This study clearly demonstrated that NIR-PIT using the EGFR Affibody–IR700Dye conjugate represents a new treatment strategy for EGFR-positive salivary gland cancer that is less invasive and improves the quality of life. This evidence concerns the gene EGFR and salivary gland cancer.